Recent advances in the treatment and monitoring of HIV-1 infection have substantially diminished HIV-associated illness and mortality, but the management of HIV-infected patients has become increasingly complex. We are conducting studies that address some of these issues, including: characterization of immune recovery in persons with advanced HIV infection, including studies of discontinuation of prophylaxis against opportunistic infections; management of antiretoviral therapy in individuals with advanced infection; and determination of viral load kinetics after interruption of successful anti-retroviral therapy. In a group of patients with inactive CMV retinitis, we demonstrated the safety of discontinuing anti-CMV maintenance therapy after HAART-induced increases in CD4 cell counts were observed. Immune recovery vitritis occurred in this setting, possibly as a result of enhanced immune responses against CMV antigens. Our observations contributed to the 1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus. Mathematical modeling of HIV viral load kinetics in a group of HIV-infected persons who were naive to therapy and were subsequently treated suggests that HIV continues to disseminate in spite of apparent control of HIV in the plasma. In persons who discontinued antiretroviral therapy after having had a prolonged period of effective suppression, HIV viral levels in the plasma returned to levels approximating their baseline levels, suggesting that even prolonged antiretroviral therapy will not lead to long-term durable benefits without continued therapy. We continue work on a database designed to capture clinical and laboratory data for the dual purposes of rapid access to data for patient care and research use. We continue our efforts to improve access to clinical trials by local minority populations through an outreach that includes a close relationship with local clinics for the medically underserved.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI000390-17
Application #
6431558
Study Section
(LIR)
Project Start
Project End
Budget Start
Budget End
Support Year
17
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Niaid Extramural Activities
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Petersen, Tess; Lee, Yu-Jin; Osinusi, Anu et al. (2016) Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin. AIDS Res Hum Retroviruses 32:660-7
Shrivastava, Shikha; TrehanPati, Nirupama; Kottilil, Shyam et al. (2013) Decline in immature transitional B cells after hepatitis B vaccination in hepatitis B positive newborns. Pediatr Infect Dis J 32:792-4
Nussenblatt, Veronique; McLaughlin, Mary; Rehm, Catherine A et al. (2007) Immunodeficiency and intrinsic IFN resistance are associated with viral breakthrough to HCV therapy in HIV-coinfected patients. AIDS Res Hum Retroviruses 23:1354-9
Neumann, Au; Polis, Ma; Rozenberg, L et al. (2007) Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients. AIDS 21:1855-65
Meyers, Jennifer Hartt; Justement, J Shawn; Hallahan, Claire W et al. (2007) Impact of HIV on cell survival and antiviral activity of plasmacytoid dendritic cells. PLoS ONE 2:e458
Malaspina, Angela; Moir, Susan; Chaitt, Doreen G et al. (2007) Idiopathic CD4+ T lymphocytopenia is associated with increases in immature/transitional B cells and serum levels of IL-7. Blood 109:2086-8
Kottilil, Shyam; Jackson, Julia O; Reitano, Kristin N et al. (2007) Innate immunity in HIV infection: enhanced susceptibility to CD95-mediated natural killer cell death and turnover induced by HIV viremia. J Acquir Immune Defic Syndr 46:151-9
Lempicki, R A; Polis, M A; Yang, J et al. (2006) Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons. J Infect Dis 193:1172-7
Kottilil, Shyam; Shin, Kyungmin; Jackson, Julia O et al. (2006) Innate immune dysfunction in HIV infection: effect of HIV envelope-NK cell interactions. J Immunol 176:1107-14
Pau, Alice K; McLaughlin, Mary M; Hu, Zonghui et al. (2006) Predictors for hematopoietic growth factors use in HIV/HCV-coinfected patients treated with peginterferon alfa 2b and ribavirin. AIDS Patient Care STDS 20:612-9

Showing the most recent 10 out of 52 publications